- Home
- XERS vs SLP Comparison
XERS vs SLP Comparison
Compare XERS & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- SLP
- Stock Information
- Founded
- XERS 2005
- SLP 1996
- Country
- XERS United States
- SLP United States
- Employees
- XERS N/A
- SLP N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- SLP EDP Services
- Sector
- XERS Health Care
- SLP Technology
- Exchange
- XERS Nasdaq
- SLP Nasdaq
- Market Cap
- XERS 628.7M
- SLP 675.9M
- IPO Year
- XERS 2018
- SLP 1997
- Fundamental
- Price
- XERS $5.07
- SLP $26.50
- Analyst Decision
- XERS Strong Buy
- SLP Buy
- Analyst Count
- XERS 6
- SLP 8
- Target Price
- XERS $6.25
- SLP $47.83
- AVG Volume (30 Days)
- XERS 2.2M
- SLP 274.1K
- Earning Date
- XERS 05-08-2025
- SLP 07-01-2025
- Dividend Yield
- XERS N/A
- SLP 0.19%
- EPS Growth
- XERS N/A
- SLP N/A
- EPS
- XERS N/A
- SLP 0.36
- Revenue
- XERS $222,551,000.00
- SLP $78,564,000.00
- Revenue This Year
- XERS $33.96
- SLP $30.21
- Revenue Next Year
- XERS $19.87
- SLP $11.83
- P/E Ratio
- XERS N/A
- SLP $88.43
- Revenue Growth
- XERS 29.88
- SLP 21.49
- 52 Week Low
- XERS $1.96
- SLP $23.01
- 52 Week High
- XERS $6.07
- SLP $50.11
- Technical
- Relative Strength Index (RSI)
- XERS 54.35
- SLP 41.21
- Support Level
- XERS $4.71
- SLP $31.79
- Resistance Level
- XERS $5.09
- SLP $34.01
- Average True Range (ATR)
- XERS 0.22
- SLP 1.39
- MACD
- XERS -0.00
- SLP -0.18
- Stochastic Oscillator
- XERS 58.93
- SLP 9.15
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.